| # | Pathway | Proteins |
|---|
| 1 | Ribosome | ENSAPLP00000004886, ENSAPLP00000005418, ENSAPLP00000011518, ENSAPLP00000011353, ENSAPLP00000009200, ENSAPLP00000015238, ENSAPLP00000015617, ENSAPLP00000006691, ENSAPLP00000010726, ENSAPLP00000001900 |
| 2 | Salmonella infection | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000015489, ENSAPLP00000009311, ENSAPLP00000009981, ENSAPLP00000006991 |
| 3 | Protein digestion and absorption | ENSAPLP00000008210, ENSAPLP00000012993, ENSAPLP00000000439, ENSAPLP00000014622 |
| 4 | Dilated cardiomyopathy | ENSAPLP00000012522, ENSAPLP00000009107, ENSAPLP00000011291, ENSAPLP00000012136, ENSAPLP00000003991 |
| 5 | Regulation of actin cytoskeleton | ENSAPLP00000009727, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000005411, ENSAPLP00000015489, ENSAPLP00000009981, ENSAPLP00000006991, ENSAPLP00000013090 |
| 6 | Shigellosis | ENSAPLP00000009727, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009981 |
| 7 | Bacterial invasion of epithelial cells | ENSAPLP00000011991, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009981, ENSAPLP00000015963 |
| 8 | Vascular smooth muscle contraction | ENSAPLP00000005411, ENSAPLP00000015489, ENSAPLP00000006991, ENSAPLP00000013090 |
| 9 | Transcriptional misregulation in cancer | ENSAPLP00000011291, ENSAPLP00000013972, ENSAPLP00000014652 |
| 10 | Renin-angiotensin system | ENSAPLP00000004168, ENSAPLP00000015747 |
| 11 | Glutathione metabolism | ENSAPLP00000007665, ENSAPLP00000007097, ENSAPLP00000001822 |
| 12 | Arginine and proline metabolism | ENSAPLP00000008767, ENSAPLP00000007097, ENSAPLP00000010692 |
| 13 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000012522, ENSAPLP00000009107, ENSAPLP00000012136, ENSAPLP00000003991 |
| 14 | Cardiac muscle contraction | ENSAPLP00000012136, ENSAPLP00000003991, ENSAPLP00000014736 |
| 15 | Malaria | ENSAPLP00000015337, ENSAPLP00000011743 |
| 16 | Focal adhesion | ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000005411, ENSAPLP00000009311, ENSAPLP00000000439, ENSAPLP00000014622, ENSAPLP00000013090 |
| 17 | ECM-receptor interaction | ENSAPLP00000009107, ENSAPLP00000004826, ENSAPLP00000000439, ENSAPLP00000014622 |
| 18 | Proteoglycans in cancer | ENSAPLP00000009107, ENSAPLP00000013972, ENSAPLP00000003050, ENSAPLP00000009311, ENSAPLP00000004826, ENSAPLP00000013831 |
| 19 | Taurine and hypotaurine metabolism | ENSAPLP00000007665 |
| 20 | Amoebiasis | ENSAPLP00000011291, ENSAPLP00000004168, ENSAPLP00000014622, ENSAPLP00000004050 |
| 21 | Arachidonic acid metabolism | ENSAPLP00000007665, ENSAPLP00000001822 |
| 22 | Leukocyte transendothelial migration | ENSAPLP00000009107, ENSAPLP00000013972, ENSAPLP00000003050, ENSAPLP00000013090 |
| 23 | Leishmaniasis | ENSAPLP00000009107, ENSAPLP00000011291 |
| 24 | Cyanoamino acid metabolism | ENSAPLP00000007665 |
| 25 | Systemic lupus erythematosus | ENSAPLP00000011291, ENSAPLP00000004168, ENSAPLP00000001720 |
| 26 | Fc gamma R-mediated phagocytosis | ENSAPLP00000011291, ENSAPLP00000003050, ENSAPLP00000009981 |
| 27 | VEGF signaling pathway | ENSAPLP00000003050, ENSAPLP00000004050 |
| 28 | Tight junction | ENSAPLP00000015489, ENSAPLP00000012466, ENSAPLP00000006991, ENSAPLP00000013090 |
| 29 | Amyotrophic lateral sclerosis (ALS) | ENSAPLP00000003050, ENSAPLP00000001822 |
| 30 | Asthma | ENSAPLP00000011291 |
| 31 | B cell receptor signaling pathway | ENSAPLP00000011291, ENSAPLP00000003050 |
| 32 | Phagosome | ENSAPLP00000009107, ENSAPLP00000011291, ENSAPLP00000003050, ENSAPLP00000009350 |
| 33 | Type I diabetes mellitus | ENSAPLP00000004358 |
| 34 | Thyroid hormone synthesis | ENSAPLP00000009350, ENSAPLP00000001822 |
| 35 | Choline metabolism in cancer | ENSAPLP00000003050, ENSAPLP00000009981 |
| 36 | Natural killer cell mediated cytotoxicity | ENSAPLP00000011291, ENSAPLP00000003050 |
| 37 | Fc epsilon RI signaling pathway | ENSAPLP00000011291, ENSAPLP00000003050 |
| 38 | Aminoacyl-tRNA biosynthesis | ENSAPLP00000008235, ENSAPLP00000015625 |
| 39 | Viral carcinogenesis | ENSAPLP00000015706, ENSAPLP00000003050, ENSAPLP00000001720, ENSAPLP00000014652 |
| 40 | Viral myocarditis | ENSAPLP00000011291, ENSAPLP00000003050 |
| 41 | PI3K-Akt signaling pathway | ENSAPLP00000009107, ENSAPLP00000011291, ENSAPLP00000003050, ENSAPLP00000000439, ENSAPLP00000014622 |
| 42 | Allograft rejection | ENSAPLP00000011291 |
| 43 | Intestinal immune network for IgA production | ENSAPLP00000011291 |
| 44 | Epstein-Barr virus infection | ENSAPLP00000015706, ENSAPLP00000011291, ENSAPLP00000014652, ENSAPLP00000004050 |
| 45 | RNA degradation | ENSAPLP00000014331, ENSAPLP00000004358 |
| 46 | Neuroactive ligand-receptor interaction | ENSAPLP00000004168 |
| 47 | Primary immunodeficiency | ENSAPLP00000011291 |
| 48 | Autoimmune thyroid disease | ENSAPLP00000011291 |
| 49 | Small cell lung cancer | ENSAPLP00000009107, ENSAPLP00000014622 |
| 50 | Histidine metabolism (no map in kegg database) | ENSAPLP00000008767 |
| 51 | Regulation of lipolysis in adipocytes | ENSAPLP00000005715 |
| 52 | Bladder cancer | ENSAPLP00000013972 |
| 53 | Notch signaling pathway | ENSAPLP00000014652 |
| 54 | MAPK signaling pathway | ENSAPLP00000003050, ENSAPLP00000009311, ENSAPLP00000004050 |
| 55 | Huntington's disease | ENSAPLP00000011991, ENSAPLP00000001822, ENSAPLP00000014652, ENSAPLP00000014736 |
| 56 | Rap1 signaling pathway | ENSAPLP00000009727, ENSAPLP00000009107, ENSAPLP00000003050 |
| 57 | African trypanosomiasis | ENSAPLP00000011291 |
| 58 | Hepatitis B | ENSAPLP00000013972, ENSAPLP00000004826 |
| 59 | cAMP signaling pathway | ENSAPLP00000003050, ENSAPLP00000013090 |
| 60 | Parkinson's disease | ENSAPLP00000006744, ENSAPLP00000010540, ENSAPLP00000014736 |
| 61 | Alzheimer's disease | ENSAPLP00000015337, ENSAPLP00000011743, ENSAPLP00000014736 |
| 62 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000012522, ENSAPLP00000009107 |
| 63 | Adherens junction | ENSAPLP00000003050, ENSAPLP00000009981 |
| 64 | Hematopoietic cell lineage | ENSAPLP00000011291 |
| 65 | Pathways in cancer | ENSAPLP00000009107, ENSAPLP00000013972, ENSAPLP00000003050, ENSAPLP00000014652, ENSAPLP00000014622 |
| 66 | Axon guidance | ENSAPLP00000009107, ENSAPLP00000003050 |
| 67 | Amphetamine addiction (no map in kegg database) | ENSAPLP00000014652 |
| 68 | TGF-beta signaling pathway | ENSAPLP00000013831 |
| 69 | Calcium signaling pathway | ENSAPLP00000011291, ENSAPLP00000005411 |
| 70 | Alcoholism | ENSAPLP00000001720, ENSAPLP00000014652 |
| 71 | cGMP-PKG signaling pathway | ENSAPLP00000005411, ENSAPLP00000013090 |
| 72 | Colorectal cancer | ENSAPLP00000003050 |
| 73 | Renin secretion | ENSAPLP00000015747 |
| 74 | Tuberculosis | ENSAPLP00000011291, ENSAPLP00000004358 |
| 75 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000012136, ENSAPLP00000003991 |
| 76 | beta-Alanine metabolism (no map in kegg database) | ENSAPLP00000008767 |
| 77 | NF-kappa B signaling pathway | ENSAPLP00000011291 |
| 78 | Pancreatic cancer | ENSAPLP00000003050 |
| 79 | Staphylococcus aureus infection | ENSAPLP00000011291 |
| 80 | Oxytocin signaling pathway | ENSAPLP00000005411, ENSAPLP00000013090 |
| 81 | Starch and sucrose metabolism | ENSAPLP00000009916 |
| 82 | Legionellosis | ENSAPLP00000004358 |
| 83 | Rheumatoid arthritis | ENSAPLP00000011291 |
| 84 | Non-alcoholic fatty liver disease (NAFLD) | ENSAPLP00000003050, ENSAPLP00000014736 |
| 85 | Toll-like receptor signaling pathway | ENSAPLP00000003050 |
| 86 | Jak-STAT signaling pathway | ENSAPLP00000010107 |
| 87 | Pertussis | ENSAPLP00000009107 |
| 88 | Endocrine and other factor-regulated calcium reabsorption | ENSAPLP00000011991 |
| 89 | Pancreatic secretion | ENSAPLP00000003050 |
| 90 | MicroRNAs in cancer | ENSAPLP00000013972, ENSAPLP00000014652 |
| 91 | Amino sugar and nucleotide sugar metabolism | ENSAPLP00000009916 |
| 92 | TNF signaling pathway | ENSAPLP00000013972 |
| 93 | Pentose phosphate pathway | ENSAPLP00000009916 |
| 94 | Renal cell carcinoma | ENSAPLP00000003050 |
| 95 | Platelet activation | ENSAPLP00000009107, ENSAPLP00000005411 |
| 96 | Synaptic vesicle cycle | ENSAPLP00000011991 |
| 97 | Measles | ENSAPLP00000011291 |
| 98 | Pyrimidine metabolism | ENSAPLP00000002225 |
| 99 | Antigen processing and presentation | ENSAPLP00000009350 |
| 100 | PPAR signaling pathway | ENSAPLP00000005715 |
| 101 | Gastric acid secretion | ENSAPLP00000005411 |
| 102 | Chronic myeloid leukemia | ENSAPLP00000014652 |
| 103 | Epithelial cell signaling in Helicobacter pylori infection | ENSAPLP00000003050 |
| 104 | Osteoclast differentiation | ENSAPLP00000003050 |
| 105 | Lysosome | ENSAPLP00000011991, ENSAPLP00000004168 |
| 106 | Cell adhesion molecules (CAMs) | ENSAPLP00000009107 |
| 107 | Cell cycle | ENSAPLP00000014652 |
| 108 | Peroxisome | ENSAPLP00000006873 |
| 109 | Proteasome | ENSAPLP00000015706 |
| 110 | Sphingolipid signaling pathway | ENSAPLP00000003050 |
| 111 | Phospholipase D signaling pathway | ENSAPLP00000011291 |
| 112 | Thyroid hormone signaling pathway | ENSAPLP00000014652 |
| 113 | Protein processing in endoplasmic reticulum | ENSAPLP00000009350, ENSAPLP00000010630 |
| 114 | Estrogen signaling pathway | ENSAPLP00000013972 |
| 115 | Glycolysis / Gluconeogenesis | ENSAPLP00000009916 |
| 116 | Wnt signaling pathway | ENSAPLP00000003050 |
| 117 | Toxoplasmosis | ENSAPLP00000009107 |
| 118 | Neurotrophin signaling pathway | ENSAPLP00000003050 |
| 119 | Pathogenic Escherichia coli infection | ENSAPLP00000009107 |
| 120 | Spliceosome | ENSAPLP00000012296, ENSAPLP00000014331 |
| 121 | Herpes simplex infection | ENSAPLP00000012296 |
| 122 | Purine metabolism | ENSAPLP00000002225 |
| 123 | Ras signaling pathway | ENSAPLP00000003050 |
| 124 | Chemokine signaling pathway | ENSAPLP00000003050 |
| 125 | HTLV-I infection | ENSAPLP00000009350 |
| 126 | Oxidative phosphorylation | ENSAPLP00000014736 |
| 127 | Endocytosis | ENSAPLP00000011991, ENSAPLP00000003542 |
| 128 | Carbon metabolism (no map in kegg database) | ENSAPLP00000009916 |
| 129 | Metabolic pathways (no map in kegg database) | ENSAPLP00000008767, ENSAPLP00000009916, ENSAPLP00000002225, ENSAPLP00000007665, ENSAPLP00000007097, ENSAPLP00000010692, ENSAPLP00000014736 |